John Renger - 21 Dec 2021 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 21 Dec 2021
Net transactions value: -$211,700
Form type: 4
Filing time: 23 Dec 2021, 16:14:31 UTC
Previous filing: 17 Dec 2021
Next filing: 28 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$25,550	+7,300	+369%	$3.50^*	9,280	21 Dec 2021	Direct	F1, F2
transaction	CERE	Common Stock	Sale	$237,250	-7,300	-79%	$32.50	1,980	21 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-7,300	-1.9%	$0.000000	380,875	21 Dec 2021	Common Stock	7,300	$3.50	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	Includes 1,980 shares acquired under the Issuer's Employee Stock Purchase Plan on May 28, 2021.
F3	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.